Maintenance Therapy in AML Comes of Age: Presentation and Discussion
While maintenance therapy has long been a standard of care in ALL and in APL, until recently there has been little evidence to support its use in non-APL AML. In this webinar we will review recent data that have led to the approval of oral azacitidine for AML maintenance, will define the optimal use of oral azacitidine for this indication, and will discuss the evolving role of maintenance therapy in FLT3-mutated AML.